Literature DB >> 18486463

TGF-beta and tumors--an ill-fated alliance.

Niki M Moutsopoulos1, Jie Wen, Sharon M Wahl.   

Abstract

Mechanisms of host defense can form an unwitting alliance with tumor cells to promote tumor progression, invasion, and dissemination to distant sites. By secreting TGF-beta, an immunoregulatory molecule designated for both promoting inflammation and dampening immune responses, the tumor tricks the host into supporting its expansion and survival. TGF-beta not only recruits leukocytes to secrete chemokines, growth factors, cytokines, and proteases in support of a tumor-friendly niche but also in a context-specific manner, incapacitates the emergent immune response. As a profound immunosuppressant, TGF-beta, both directly and through the generation of regulatory T cells, blunts immune surveillance, favoring tumor escape. Collectively, the ability of the tumor to hijack these host defense pathways can tip the balance in favor of the tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18486463      PMCID: PMC3371194          DOI: 10.1016/j.coi.2008.04.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  50 in total

1.  A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.

Authors:  Laura Strauss; Christoph Bergmann; Miroslaw Szczepanski; William Gooding; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

Review 2.  Alterations in components of the TGF-beta superfamily signaling pathways in human cancer.

Authors:  Laurence Levy; Caroline S Hill
Journal:  Cytokine Growth Factor Rev       Date:  2005-11-23       Impact factor: 7.638

3.  Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.

Authors:  Christoph Bergmann; Laura Strauss; Reinhard Zeidler; Stephan Lang; Theresa L Whiteside
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 4.  Taking dendritic cells into medicine.

Authors:  Ralph M Steinman; Jacques Banchereau
Journal:  Nature       Date:  2007-09-27       Impact factor: 49.962

Review 5.  Basics of TGF-beta and pancreatic cancer.

Authors:  Mark J Truty; Raul Urrutia
Journal:  Pancreatology       Date:  2007-09-25       Impact factor: 3.996

Review 6.  Th17 cells: a new fate for differentiating helper T cells.

Authors:  Zhi Chen; John J O'Shea
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

7.  Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment.

Authors:  Ilona Kryczek; Shuang Wei; Linhua Zou; Saleh Altuwaijri; Wojciech Szeliga; Jay Kolls; Alfred Chang; Weiping Zou
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

8.  IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.

Authors:  Thomas Korn; Estelle Bettelli; Wenda Gao; Amit Awasthi; Anneli Jäger; Terry B Strom; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

Review 9.  Interleukin-21: a new modulator of immunity, infection, and cancer.

Authors:  Katja Brandt; Prim B Singh; Silvia Bulfone-Paus; René Rückert
Journal:  Cytokine Growth Factor Rev       Date:  2007-05-16       Impact factor: 7.638

10.  Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.

Authors:  Teruo Kaiga; Marimo Sato; Hide Kaneda; Yoichiro Iwakura; Tadatoshi Takayama; Hideaki Tahara
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

View more
  25 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

Review 2.  TGFβ signaling in head and neck squamous cell carcinoma.

Authors:  R A White; S P Malkoski; X-J Wang
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

3.  Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.

Authors:  Amber M Bates; Emily A Lanzel; Fang Qian; Taher Abbasi; Shireen Vali; Kim A Brogden
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2017-05-25

4.  MKL1 potentiates lung cancer cell migration and invasion by epigenetically activating MMP9 transcription.

Authors:  X Cheng; Y Yang; Z Fan; L Yu; H Bai; B Zhou; X Wu; H Xu; M Fang; A Shen; Q Chen; Y Xu
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

5.  Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.

Authors:  Jie Wen; Nikolaos G Nikitakis; Risa Chaisuparat; Teresa Greenwell-Wild; Maria Gliozzi; Wenwen Jin; Azita Adli; Niki Moutsopoulos; Tanxia Wu; Gary Warburton; Sharon M Wahl
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 6.  Immunology and Immunotherapy of Head and Neck Cancer.

Authors:  Robert L Ferris
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

7.  TGF-β1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death.

Authors:  J Park; J Lee; W Kang; S Chang; E-C Shin; C Choi
Journal:  Cell Death Dis       Date:  2013-02-28       Impact factor: 8.469

Review 8.  Immunotherapy of human cancers using gene modified T lymphocytes.

Authors:  Juan F Vera; Malcolm K Brenner; Gianpietro Dotti
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

9.  Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.

Authors:  Yi-Lan Zhang; Jiang Li; Hao-Yuan Mo; Fang Qiu; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  Mol Cancer       Date:  2010-01-10       Impact factor: 27.401

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.